Copyright
©The Author(s) 2024.
World J Clin Oncol. Jul 24, 2024; 15(7): 848-858
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.848
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.848
gBRCA1 | Positive | Negative |
Total, n (%) | 15 (26.3) | 42 (73.7) |
Age in yr at diagnosis, mean ± SD | 42.1 ± 11 | 45.3 ± 8.7 |
Positive family history, n (%) | 8 (53.3) | 16 (38.1) |
First-degree relative, n (%) | 8 (53.3) | 9 (21.3) |
Non-first-degree relatives, n (%) | 4 (26.6) | 11 (26.1) |
H/o IVF & Rx, n (%) | 0 | 0 |
H/o hormone Rx, n (%) | 1 (6.6) | 4 (9.5) |
ECOG PS at diagnosis2, n (%) | ||
0 | 13 (86.7) | 40 (95.2) |
1 | 2 (12.3) | 2 (4.8) |
Histology at diagnosis, n (%) | ||
Invasive ductal carcinoma | 12 (80) | 35 (83.3) |
Invasive lobular carcinoma | 1 (6.6) | 4 (9.5) |
Grade at diagnosis, mean ± SD | 3 ± 0.6 | 2 ± 0.7 |
Stage at diagnosis, n (%) | ||
1 | 1 (6.6) | 0 |
2 | 7 (46.6) | 21 (50) |
3 | 4 (26.6) | 13 (31) |
4 | 3 (20) | 8 (19) |
Categories3, n (%) | ||
HER2-positive | 4 (26.6) | 12 (28.7) |
Triple-negative | 3 (20) | 8 (19.0) |
HR-positive and HER2-negative | 6 (40) | 15 (35.7) |
HR-positive and HER2-positive | 3 (20) | 6 (14.3) |
Cancer type | Patient | Stage | Response change to PARPi | Duration of PARPi | PARPi status at end of study |
BRCA+ breast cancer, 5/15 (33.3%) | 1 | II | CR–DF | 13 months+ | On Rx |
21 | II | PR–PR | 40 days | Stopped | |
3 | III | CR–DF | 17 months+ | On Rx | |
4 | IV | PR–PR | 5 months | Stopped | |
52 | IV | PR | 7 months | Stopped | |
HRD+ ovarian cancer, 4/6 (66.6%) | 1 | III | PR–DF | 15 months+ | On Rx |
2 | IV | CR–DF | 13 months+ | On Rx | |
3 | IV | SD–PRF | 20 months+ | On Rx | |
4 | IV | CR–DF | 25 months+ | On Rx |
Characteristic | HRD-positive | HRD-negative |
Total, n (%) | 6 (24) | 19 (76) |
Age years at diagnosis, mean ± SD | 56.5 ± 11 | 52.5 ± 13 |
Positive family history, n (%) | 0 | 5 (26.3) |
ECOG PS at diagnosis, n (%) | ||
0 | 5 (83.3) | 17 (89.4) |
1 | 1 (16.7) | 1 (5.3) |
2 | 0 | 1 (5.3) |
Histology, n (%) | ||
Serous | 5 (83.3) | 9 (47.3) |
Endometrioid/mucinous/clear cell | 1 (16.7) | 5 (26.3) |
Mixed | 0 | 5 (26.3) |
Grade of cancer, mean ± SD | 4 ± 0 | 4 ± 0.9 |
Stage of cancer, n (%) | ||
1 | 1 (16.7) | 2 (10.5) |
2 | 0 | 0 |
3 | 2 (33.3) | 11 (58) |
4 | 3 (50) | 6 (31.5) |
Surgical Rx, n (%) | 6 (100) | 17 (89.5) |
Primary | 2 (33.3) | 12 (63.1) |
Interval | 4 (66.7) | 5 (26.4) |
- Citation: Syed N, Chintakuntlawar AV, Vilasini D, Al Salami AM, Al Hasan R, Afrooz I, Uttam Chandani K, Chandani AU, Chehal A. Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients. World J Clin Oncol 2024; 15(7): 848-858
- URL: https://www.wjgnet.com/2218-4333/full/v15/i7/848.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i7.848